Figure 5. Responder rates at 3 months, 6 months, 12 months and at last visit in patients treated with eslicarbazepine acetate ≤1200mg daily versus >1200mg daily. Response was defined as >50% seizure frequency reduction from baseline. Statistical comparisons were conducted using the Chi-squared test. Reproduced with permission from Eisai